CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 17% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-01-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: transplantcellsubjects withstemcancer
  Phrases that lowered it: adultrelapsedevaluaterefractoryinvestigator
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 23.4% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 94.0% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 124750 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 21281 (lowers risk) · Drug's FDA history
• Maximum age: 30 (lowers risk) · Who can join
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Minimum age: 1 (lowers risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies NCT04088890 · started 2019 · scored riskier than 76% of active trials completed
• Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies NCT02315612 · started 2014 · scored riskier than 79% of active trials completed
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies NCT03448393 · started 2018 · scored riskier than 82% of active trials completed
• CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL NCT04049383 · started 2020 · scored riskier than 81% of active trials terminated
• Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma NCT01593696 · started 2012 · scored riskier than 73% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.